Analyze LCTX

ShareShare on WhatsApp Share on Facebook Share on X

Equity Research · Deep diveIT-2026-LCTX · 2026-07-30

Lineage Cell Therapeutics, Inc. (LCTX)

HealthcareBiotechnologyNYSE AmericanMarket cap $264.26M

$1.06

-0.93%

Analyst-style PDF, emailed within minutes

43/100

Mixed picture

Automated weighted score · not a recommendation

Price source: Yahoo · live price · as of 23:00 · Data: Yahoo · SEC EDGAR · FINRA · Wikidata

About the company

Market cap

$264.26M

P/E

—

Beta

1.51

Employees

Sector: HealthcareIndustry: BiotechnologyExchange: NYSE AmericanCountry: United StatesFounded: 1990 Website

What the company does

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Day range

$1.02$1.08

52-week range

$0.95$2.09

Price alert on LCTX

Get an in-app and mobile alert every time LCTX crosses a price you set.

Loading short data…

LCTX · Chart

Loading chart…

SMA20 SMA50 SMA200

Charts by TradingView

Support & resistance

Key trading levels, by timeframe

Day

Swing

Computing levels…

The technical signal compass

Sign up free and build your own trading bot with full backtesting. Live bots, real-time alerts and the bot gallery — with a Pro subscription.

Free sign-up

Lineage Cell Therapeutics, Inc. (LCTX) is trading around $1.06 (-0.93% on the last session). Its 52-week range runs from $0.95 to $2.09. Technically: 1 buy signals, 9 sell and 2 neutral. It belongs to the Healthcare sector (Biotechnology) and a 264M$ market cap. Data sourced from Yahoo · live price as of 23:00. This is data analysis only, not advice or a recommendation.

LCTX stock FAQ

What is LCTX's current price?

LCTX is trading around $1.06 (-0.93%), as of 23:00 per Yahoo · live price.

What is LCTX's 52-week price range?

Over the last 52 weeks LCTX ranged between a $0.95 low and a $2.09 high.

Which sector does LCTX belong to?

LCTX belongs to the Healthcare sector, Biotechnology industry.

Disclosure & disclaimer: All information, scores, signals and trade plans on this site are produced by an automated algorithmic system and are based on technical and quantitative data only. They do not constitute investment advice, investment marketing or a recommendation to act, and are not a substitute for personal advice from a licensed professional that accounts for your needs and circumstances. We are not investment advisors. Trading securities involves substantial risk, up to the loss of your entire investment; every decision and action is your sole responsibility. i-trade and its operators bear no liability for any direct or indirect damage arising from reliance on this information.

0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ %€ ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇% ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 01 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 #$ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 €↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1

Building the strategy

LCTX stock FAQ

What is LCTX's current price?

LCTX is trading around $1.06 (-0.93%), as of 23:00 per Yahoo · live price.

What is LCTX's 52-week price range?

Over the last 52 weeks LCTX ranged between a $0.95 low and a $2.09 high.

Which sector does LCTX belong to?

LCTX belongs to the Healthcare sector, Biotechnology industry.

Analyze LCTX

Lineage Cell Therapeutics, Inc. (LCTX)

About the company

LCTX · Chart

Support & resistance

The technical signal compass

LCTX stock FAQ

Lineage Cell Therapeutics, Inc. (LCTX)

About the company

LCTX · Chart

Support & resistance

The technical signal compass

LCTX stock FAQ

Income statement analysis

Institutional & insider data

Full analyst coverage